Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 1
2022 pubmed 12 citations

Engineered Exosomes Containing Cathelicidin/LL-37 Exhibit Multiple Biological Functions.

Su. Yajuan Y; Sharma. Navatha Shree NS; John. Johnson V JV; Ganguli-Indra. Gitali G; Indra. Arup K AK; Gombart. Adrian F AF; Xie. Jingwei J

Key Findings

  • Engineered exosomes contain much higher levels of LL‑37 than normal exosomes
  • LL‑37‑rich exosomes kill bacteria in lab tests
  • They promote blood‑vessel‑like tube formation and skin cell growth and movement

Practical Outcomes

  • At this stage the work is a proof‑of‑concept and not a DIY protocol. It shows that delivering LL‑37 via exosomes could be a future therapeutic route, but producing such exosomes requires specialized lab techniques and equipment.

Summary

Scientists made tiny vesicles (exosomes) from immune cells that were loaded with a natural antimicrobial peptide called LL‑37. These boosted exosomes can kill bacteria and help blood vessels and skin cells grow, suggesting they could be used for infection control and wound healing, but the method is complex and not ready for personal use.

Abstract

Exosomes show great potential in diagnostic and therapeutic applications. Inspired by the human innate immune defense, herein, we report engineered exosomes derived from monocytic cells treated with immunomodulating compounds 1&#x3b1;,25-dihydroxyvitamin D<sub>3,</sub> and CYP24A1 inhibitor VID400 which are slowly released from electrospun nanofiber matrices. These engineered exosomes contain significantly more cathelicidin/LL-37 when compared with exosomes derived from either untreated cells or Cathelicidin Human Tagged ORF Clone transfected cells. In addition, such exosomes exhibit multiple biological functions evidenced by killing bacteria, facilitating human umbilical vein endothelial cell tube formation, and enhancing skin cell proliferation and migration. Taken together, the engineered exosomes developed in this study can be used as therapeutics alone or in combination with other biomaterials for effective infection management, wound healing, and tissue regeneration.

Study Information

Provider

pubmed

Year

2022

Date

2022-08-12T00:00:00.000Z

DOI

10.1002/adhm.202200849

Citations

12

References

4